

*Applicant: Phillips et al.*  
*Application Serial No. 09/735,363*  
*Amendment and Response to Non-Final Office Action*  
*Page 2 of 8*

### AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A composition, comprising a ~~2 to 20 base~~ 3'-OH, 5'-OH synthetic phosphodiester nucleotide sequence, and a pharmaceutically acceptable carrier, wherein the synthetic phosphodiester nucleotide sequence is selected from the group consisting of ~~SEQ ID NOs: 8, 10, 25, 26, 41, 43, 45 and 46~~ SEQ ID NOs: 8, 10, 25, 42, 43 and 45.

2-4. (Cancelled)

5. (Previously presented) The composition of Claim 1, further comprising a chemotherapeutic agent.

6-9. (Cancelled)

10. (Previously presented) The composition of Claim 5, wherein the chemotherapeutic agent is an antimetabolite, an alkylating agent, or a hormone antagonist.

11-58. (Cancelled)

59. (Previously presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:8.

60. (Cancelled)

61. (Previously presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:10.

ATTN:LIB02 185341 1

*Applicant: Phillips et al.*  
*Application Serial No. 09/735,363*  
*Amendment and Response to Non-Final Office Action*  
*Page 3 of 8*

62. (Previously presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:25.

63-64. (Cancelled)

65. (Previously presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:42.

66. (Previously presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:43.

67. (Previously presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:45.

68. (Cancelled)

ATLLB02 1R5341.1